Literature DB >> 21294950

Treatment of angiostrongyliasis using a combination of albendazole and dexamethasone: the results of a retrospective and comparative study.

Z Diao1, J Wang, H Qi, X Li, X Zheng, C Yin.   

Abstract

As the information available on the treatment of angiostrongyliasis with a combination of albendazole and dexamethasone is limited, the efficacy of such therapy was assessed using data collected during the 2006 outbreak of angiostrongyliasis in Beijing. In a retrospective and controlled study, 35 patients treated with albendazole-dexamethasone (given 20 mg albendazole/kg and 3 mg dexamethasone daily for 7 days) were compared with 34 controls who were treated only symptomatically (with acetaminophen or other drugs). Compared with the controls, the patients given the combination were less likely to have headaches after 7 days (P = 0·038), tended to have headaches that cleared quicker (P = 0·010), and received fewer doses of acetaminophen (P = 0·036). Since no serious adverse effects were observed, a 1-week treatment with a combination of albendazole and dexamethasone appears both safe and beneficial in the treatment of angiostrongyliasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21294950      PMCID: PMC4089795          DOI: 10.1179/136485910X12851868780342

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  10 in total

1.  A 1-week course of corticosteroids in the treatment of eosinophilic meningitis.

Authors:  Kittisak Sawanyawisuth; Panita Limpawattana; Ploysyne Busaracome; Bundit Ninpaitoon; Verajit Chotmongkol; Pewpan M Intapan; Supawadee Tanawirattananit
Journal:  Am J Med       Date:  2004-11-15       Impact factor: 4.965

2.  Albendazole therapy for eosinophilic meningitis caused by Angiostrongylus cantonensis.

Authors:  Suthipun Jitpimolmard; Kittisak Sawanyawisuth; Nimit Morakote; Athasit Vejjajiva; Montien Puntumetakul; Kanokwan Sanchaisuriya; Wongwiwat Tassaneeyakul; Wichittra Tassaneeyakul; Narumanas Korwanich
Journal:  Parasitol Res       Date:  2006-12-20       Impact factor: 2.289

3.  Treatment of eosinophilic meningitis with a combination of prednisolone and mebendazole.

Authors:  Verajit Chotmongkol; Kookwan Sawadpanitch; Kittisak Sawanyawisuth; Sitichoke Louhawilai; Panita Limpawattana
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

4.  Corticosteroid treatment of eosinophilic meningitis.

Authors:  V Chotmongkol; K Sawanyawisuth; Y Thavornpitak
Journal:  Clin Infect Dis       Date:  2000-09-26       Impact factor: 9.079

5.  An outbreak of eosinophilic meningitis caused by Angiostrongylus cantonensis in travelers returning from the Caribbean.

Authors:  Trevor J Slom; Margaret M Cortese; Susan I Gerber; Roderick C Jones; Timothy H Holtz; Adriana S Lopez; Carlos H Zambrano; Robert L Sufit; Yuwaporn Sakolvaree; Wanpen Chaicumpa; Barbara L Herwaldt; Stuart Johnson
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

6.  Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid.

Authors:  Verajit Chotmongkol; Chatchawan Wongjitrat; Kookwan Sawadpanit; Kittisak Sawanyawisuth
Journal:  Southeast Asian J Trop Med Public Health       Date:  2004-03       Impact factor: 0.267

Review 7.  Human angiostrongyliasis.

Authors:  Qiao-Ping Wang; De-Hua Lai; Xing-Quan Zhu; Xiao-Guang Chen; Zhao-Rong Lun
Journal:  Lancet Infect Dis       Date:  2008-10       Impact factor: 25.071

8.  Comparison of prednisolone plus albendazole with prednisolone alone for treatment of patients with eosinophilic meningitis.

Authors:  Verajit Chotmongkol; Suvicha Kittimongkolma; Kanigar Niwattayakul; Pewpan M Intapan; Yupa Thavornpitak
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345

Review 9.  Treatment of angiostrongyliasis.

Authors:  Kanlayanee Sawanyawisuth; Kittisak Sawanyawisuth
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-05-27       Impact factor: 2.184

10.  Emerging angiostrongyliasis in Mainland China.

Authors:  Shan Lv; Yi Zhang; Peter Steinmann; Xiao-Nong Zhou
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

  10 in total
  6 in total

1.  Albendazole-Schisandrin B Co-Therapy on Angiostrongylus cantonensis-Induced Meningoencephalitis in Mice.

Authors:  Ho Yin Pekkle Lam; Ting-Ruei Liang; Shinn-Jong Jiang; Shih-Yi Peng
Journal:  Biomolecules       Date:  2020-07-05

2.  A blind passenger: a rare case of documented seroconversion in an Angiostrongylus cantonensis induced eosinophilic meningitis in a traveler visiting friends and relatives.

Authors:  Tobias Brummaier; Sonja Bertschy; Kornelius Arn; Thomas Treumann; Marie-Therese Ruf; Beatrice Nickel; Daniel H Paris; Andreas Neumayr; Johannes Blum
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-04-15

3.  Guidelines for the diagnosis and treatment of neuroangiostrongyliasis: updated recommendations.

Authors:  Vernon Ansdell; Kenton J Kramer; Jourdan K McMillan; William L Gosnell; Gerald S Murphy; B C Meyer; Elizabeth U Blalock; Johnnie Yates; Louis Lteif; Olivia A Smith; Marian Melish
Journal:  Parasitology       Date:  2020-07-30       Impact factor: 3.234

4.  Co-Therapy of Albendazole and Dexamethasone Reduces Pathological Changes in the Cerebral Parenchyma of Th-1 and Th-2 Dominant Mice Heavily Infected with Angiostrongylus cantonensis: Histopathological and RNA-seq Analyses.

Authors:  Kai-Yuan Jhan; Chien-Ju Cheng; Shih-Ming Jung; Yi-Jen Lai; Kuang-Yao Chen; Lian-Chen Wang
Journal:  Biomolecules       Date:  2021-04-06

5.  Benzaldehyde Attenuates the Fifth Stage Larval Excretory-Secretory Product of Angiostrongylus cantonensis-Induced Injury in Mouse Astrocytes via Regulation of Endoplasmic Reticulum Stress and Oxidative Stress.

Authors:  Kuang-Yao Chen; Yi-Ju Chen; Chien-Ju Cheng; Kai-Yuan Jhan; Lian-Chen Wang
Journal:  Biomolecules       Date:  2022-01-21

Review 6.  Clinical Efficacy and Safety of Albendazole and Other Benzimidazole Anthelmintics for Rat Lungworm Disease (Neuroangiostrongyliasis): A Systematic Analysis of Clinical Reports and Animal Studies.

Authors:  John Jacob; Argon Steel; Zhain Lin; Fiona Berger; Katrin Zöeller; Susan Jarvi
Journal:  Clin Infect Dis       Date:  2022-04-09       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.